Objective Triple therapy with rabeprazole (RPZ), amoxicillin (AMPC) and metronidazole (MNZ) (RPZ+ AMPC+MNZ therapy: RAM therapy) has been approved by the Japanese Ministry of Health, Labour and Welfare as a second-line therapy for Helicobacter pylori-positive gastric and duodenal ulcers in Japan. The present multicenter prospective observational study aimed to investigate the safety and efficacy of RAM therapy in clinical practice. Methods Patients with H. pylori-positive gastric or duodenal ulcers (including ulcer scars) in whom firstline therapy was unsuccessful were administered 10 mg of RPZ, 750 mg of AMPC and 250 mg of MNZ twice daily for seven days (total: 14 doses) based on an approved dose and regimen. Patient background factors, including complications, previous medical history, concomitant drugs, eradication results and adverse events were recorded by the investigator. Results The incidence of adverse drug reactions was 2.21% and the H. pylori eradication rate was 92.8%. Subgroup analyses performed to investigate the patient background factors affecting safety and efficacy revealed no factors that significantly affected the incidence of adverse drug reactions or the H. pylori eradication rate. Conclusion Amid reports of decreased eradication rates with clarithromycin-based first-line therapy, the >90% H. pylori eradication rate achieved in the present study demonstrates the clinical efficacy of RAM therapy in subjects in whom first-line therapy is unsuccessful.
Introduction
Helicobacter pylori is a microaerophilic, Gram-negative bacillus that inhabits the gastric mucus and gastric mucosa. Against a background of chronic inflammation of the gastric mucosa following persistent infection, H. pylori plays a major role in the pathogenesis and pathological conditions of various upper gastrointestinal diseases, including gastric ulcers, duodenal ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. The guidelines of the Japanese Society for Helicobacter Research also report associations of H. pylori with non-gastrointestinal diseases, including idiopathic thrombocytopenic purpura, irondeficiency anemia and chronic urticaria (1) .
H. pylori eradication therapy is effective for accelerating healing and inhibiting the recurrence of gastric and duodenal ulcers (2, 3) and is recommended in various guidelines as a first-line therapy for H. pylori-positive gastric and duodenal ulcers (1, 4, 5) . In Japan, triple therapy with a proton pump inhibitor (PPI) and two different antimicrobial agents has been approved for H. pylori eradication. First-line eradica-tion therapy with a PPI, amoxicillin (AMPC) and clarithromycin (CAM) and second-line eradication therapy with a PPI, AMPC and metronidazole (MNZ) are used in clinical practice to treat gastric ulcers, duodenal ulcers, gastric MALT lymphoma and idiopathic thrombocytopenic purpura and are administered after endoscopic treatment for early gastric cancer.
Rabeprazole (RPZ) is an acid secretion-inhibiting drug synthesized and developed by Eisai Co., Ltd. (Tokyo, Japan). This PPI provides effective and lasting gastric acid secretion-inhibiting actions that work by blocking the H+, K+-ATPase (proton pump) in the final stage of gastric acid secretion in gastric parietal cells.
In Japan, RPZ was approved in August 2007 for use in H. pylori second-line eradication therapy for the treatment of patients in whom first-line eradication therapy is unsuccessful based on data from the literature without conducting clinical trials. Following approval, we investigated the safety and efficacy in clinical practice of second-line eradication therapy with RPZ, AMPC and MNZ (RPZ+AMPC+MNZ therapy: RAM therapy) for gastric and duodenal ulcers.
Materials and Methods

Subjects and study design
This study was a multicenter prospective observational study conducted between April 2008 and June 2010.
The subjects comprised patients with H. pylori-positive gastric or duodenal ulcers (including ulcer scars) in whom RAM therapy was performed for the first time after the administration of H. pylori first-line eradication therapy with a three-drug combination of a PPI (RPZ, omeprazole or lansoprazole), AMPC and CAM was unsuccessful. Patients with conditions contraindicating any of the drugs and those judged to be ineligible by the investigator were excluded.
The subjects were administered RAM therapy (RPZ 10 mg+AMPC 750 mg+MNZ 250 mg) twice daily for seven days (total: 14 doses).
A central registration method was used in which the investigators faxed patient information to a central registration center within six days of the day on which RAM therapy was initiated, which was taken as the first day.
This study was conducted in compliance with the Good Post-marketing Study Practice (GPSP), a ministerial ordinance of the Ministry of Health, Labour and Welfare of Japan.
Evaluation of H. pylori infection and eradication
Diagnosis of H. pylori infection and assessment of H. pylori eradication were made using rapid urease tests, histology, culture, urea breath tests, measurement of H. pylori antibodies or measurement of H. pylori antigens in feces, as recommended by the Japanese Society for Helicobacter Research (1). Assessment of H. pylori eradication was made at least four weeks after the completion of eradication therapy, in accordance with the Japanese Society for Helicobacter Research guidelines.
Endpoints and statistical analysis
The efficacy endpoints were the overall eradication rate and the eradication rates according to each patient background factor ( Table 1 ). The safety endpoints were the overall incidence of adverse drug reactions and the incidence of adverse drug reactions according to each patient background factor ( Table 2) .
The eradication rate (the percentage of subjects in the efficacy analysis set who were H. pylori-negative) and the incidence of adverse drug reactions (the percentage of subjects in the safety analysis set with an occurrence of an adverse drug reaction) were calculated together with 95% confidence intervals (CIs). The F distribution was used in calculating the 95% CIs.
As factor analyses for efficacy and safety, subgroup analyses of the eradication rate and the incidence of adverse drug reactions were conducted with patient background factors as stratification factors. An interval estimation based on the F distribution was used in calculating 95% CIs. The patient background factors affecting the eradication rate and the incidence of adverse drug reactions were investigated by calculating statistical probability using the χ 2 test or Fisher's exact probability test. Two-sided significance levels of 5% were used for the exploratory analysis.
Results
Patients
A total of 143 patients from 37 clinical departments in 36 hospitals were registered between April 2008 and September 2009. Survey forms were obtained for all patients. Of the 143 patients for whom survey forms were obtained, 136 were evaluated for the safety analysis set after excluding seven patients who failed to return for visits after the start of RAM therapy. Of the patients in the safety analysis set, 125 were evaluated for the efficacy analysis set after excluding 11 patients who deviated from the schedule for assessment of H. pylori eradication or in whom assessment of H. pylori eradication could not be determined.
Safety
The patient background factors and the incidence of adverse drug reactions for each patient background factor for the 136 patients in the safety analysis set are shown in Table 1.
The 136 safety analysis subjects included 77 men (56.6%) and 59 women (43.4%). RAM therapy was not administered to any pregnant women. This set included 44 elderly patients (32.4%) ! 65 years old, 53 (39.0%) patients with complications, 72 (52.9%) patients taking concomitant drugs, 84 (61.8%) patients with gastric ulcers and 109 (80.2%) patients with ulcer scars. Compliance with the regimen was good, with nearly all patients (135 patients, 99.3%) taking the drugs "as instructed" (i.e., reporting 100% compliance). Three adverse drug reactions occurred in three patients, thus giving an adverse drug reaction rate of 2.21% (3/136). None of the adverse drug reactions were serious, consisting of diarrhea in two cases and dysgeusia in one case. One case of diarrhea occurred four days after the start of RAM therapy and resolved spontaneously within three days. The other case of diarrhea occurred on the day RAM therapy started and resolved after 43 days. The case of dysgeusia occurred five days after the start of RAM therapy, with the patient recovering the next day. Eradication therapy was not discontinued due to adverse drug reactions in any case.
Factors affecting the incidence of adverse drug reactions were investigated with subgroup analyses according to patient background factors. The results revealed no significant differences.
Efficacy
The patient background factors and the H. pylori eradication rates for each patient background factor for the 125 patients in the efficacy analysis set are shown in Table 2 . The 125 efficacy analysis subjects included 74 men (59.2%) and 51 women (40.8%). The patients evaluated in the efficacy analysis set included 40 elderly patients (32.0%) ! 65 years old, 47 (37.6%) patients with complications, 64 (51.2%) patients taking concomitant drugs, 76 (60.8%) patients with gastric ulcers and 101 (80.8%) patients with ulcer scars. Compliance with the regimen was good, with all patients taking the drugs "as instructed" (i.e., reporting 100% compliance). The most frequently used evaluation method during the post-treatment period was the urea breath test.
The overall H. pylori eradication rate was 92.8% (116/ 125). Factors affecting the H. pylori eradication rate were investigated with subgroup analyses according to the patient background factors. The results revealed no significant differences.
Three patients for whom the assessment of H. pylori eradication could not be determined were excluded from the group of 136 subjects in the safety analysis set. The time to assessment of H. pylori eradication for the remaining 133 patients was <4 weeks in eight patients, 4 to <8 weeks in 60 patients and ! 8 weeks in 65 patients. 
Discussion
This study represents the first nationwide report investigating the safety and efficacy of second-line H. pylori eradication therapy since approval was granted in Japan.
Three adverse drug reactions occurred in three patients, for an incidence of adverse drug reactions of 2.21% (3/136). This is comparable to previously reported incidences of adverse drug reactions associated with RAM therapy (0% (6), 8.3% (7)). Diarrhea and dysgeusia represent well-known adverse drug reactions resulting from H. pylori eradication therapy and are described in the package inserts for all drugs approved for use in RAM therapy. The number of days until the onset of adverse drug reactions was zero days in one case (on the day eradication therapy was started), four days in one case and five days in one case. These adverse drug reactions occurred during the administration of H. pylori eradication therapy. The outcome of these adverse drug reactions was recovery in all cases. The number of days until recovery was one, three and 43 days. The adverse drug reactions that occurred in this study were thus wellknown adverse drug reactions associated with H. pylori eradication therapy. None of the reactions were serious and the outcomes were good; therefore, no problems with respect to the tolerance of RAM therapy were identified.
The major cause of the decreased eradication rates observed with eradication therapy is drug resistance. For firstline therapies, a decreased eradication rate and an increased CAM resistance rate has become problematic (1, 8) . However, the rates of H. pylori strain resistance to the MNZ used in second-line therapy in Japan have been reported to The eradication rates associated with RAM therapy in Japan have been reported to be within the range of 88-100% (6, 7, (11) (12) (13) . The guidelines of the Japanese Society for Helicobacter Research state that, while administration periods vary from five to 10 days, the eradication rate achieved with second-line eradication therapy is 81-96% (1). This shows that the percentage of H. pylori strains resistant to MNZ in Japan is low, while the H. pylori eradication rate associated with second-line therapy is thought to be approximately 90%. The eradication rate of 92.8% observed in the present study is comparable to that cited in previous reports, indicating the effective potency of RAM therapy.
The good eradication rate of >90% achieved in this study may be associated with the properties of RPZ. With this eradication therapy, gastric pH rises due to the effects of the PPI and is maintained in the neutral range, allowing the antimicrobial agents to display good antimicrobial activity. Achieving sufficient gastric acid secretion-inhibiting effects is important, and a correlation is thought to exist between gastric pH and the success of H. pylori eradication therapy (14) . RPZ is known to increase gastric pH to between 6 and 8 more rapidly and reliably than other PPIs and to effectively inhibit nocturnal secretion of gastric acid (15) (16) (17) (18) (19) . The CYP2C19 genotype is also known to be a factor that affects the eradication rate (20) . CYP2C19 is the main metabolizer of PPIs, with patients classified broadly as extensive metabolizers (EMs) or poor metabolizers (PMs). The eradication rate is thought to be lower in EM patients with better metabolism (20) . However, RPZ shows a lower metabolic dependence on CYP2C19 than other PPIs (21) (22) (23) , and the eradication rate is also thought to be less affected by genotype (24) . Additionally, RPZ is known to exhibit more potent inhibitory effects on H. pylori proliferation and motility than other PPIs (25) . A strong gastric acid-inhibiting effect is thus obtained rapidly from the first day of administration of RPZ, and the properties of RPZ are thought to have contributed to the good eradication rate achieved in this study.
According to the Japanese Society for Helicobacter Research guidelines, the time from completion of eradication therapy to assessment of H. pylori eradication should be set at more than four weeks. In this study, eradication status was determined at ! 8 weeks in more than half of the patients.
The present study confirmed the efficacy and safety of RAM therapy in H. pylori-positive gastric ulcer or duodenal ulcer patients in clinical practice. The adverse drug reactions encountered were well-known adverse drug reactions associated with H. pylori eradication therapy and were not serious. Adverse drug reactions thus do not appear to be problematic with this regimen. Amid reports of decreased eradication rates associated with first-line eradication therapy with CAM (1), the use of RAM therapy, with H. pylori eradication rates exceeding 90%, appears likely to be clinically useful.
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